Bristol-Myers Squibb | Patient Daily

Bristol-Myers Squibb

Press release submission | Aug 9, 2020

BRISTOL-MYERS SQUIBB: Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma

Press release submission | Feb 16, 2020

BRISTOL-MYERS SQUIBB: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Carol Ostrow | Dec 27, 2017

Restrictions on Opdivo combination trials for multiple myeloma treatment lifted by FDA

Carol Ostrow | Dec 27, 2017

Seattle Genetics, Bristol-Myers Squibb report Hodgkin treatment study interim results

Carol Ostrow | Dec 26, 2017

Bristol-Myers Squibb, Pfizer, others aim to raise awareness of stroke risk in atrial fibrillation patients

Robert Hadley | Nov 8, 2017

Europe agency approves expanded use of Bristol-Myers Squibb’s Opdivo to treat advanced melanoma

Carol Ostrow | Oct 14, 2017

Opdivo approved for treating certain liver cancer patients

Carol Ostrow | Oct 1, 2017

AbbVie, Bristol-Myers Squibb collaborate on anti-cancer regimen to target lung tumors

Trending

Patient Daily News Service | Jan 22, 2025

National Pharmacists Group to DOGE: Start search for 'waste and inefficiencies in federal programs' with the pharmacy benefit managers

+ Pharmaceuticals

Patient Daily | Jan 17, 2025

Understanding symptoms and treatment options for long-term effects of COVID-19

Patient Daily News Service | Jan 16, 2025

FTC Chair: Report Finds 'Three Major Pharmacy Benefit Managers Hiked Costs for a Wide Range of Lifesaving Drugs, Including Medications to Treat Heart Disease and Cancer'